BIOMAT Database Logo BIOMAT Database Logo

Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. 1985

M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally

A sensitive and specific radioimmunoassay for [6-D-tryptophan]luteinizing hormone-releasing hormone [( D-Trp6]LH-RH) was developed and used for following the rate of liberation of [D-Trp6]LH-RH from a long-acting delivery system based on a microcapsule formulation. Rabbit antibodies were generated against [D-Trp6]LH-RH conjugated to bovine serum albumin with glutaraldehyde. Crossreactivity with LH-RH was less than 1%; there was no significant crossreactivity with other peptides. The minimal detectable dose of [D-Trp6]LH-RH was 2 pg per tube. Intra- and interassay coefficients of variation were 8% and 10%, respectively. The radioimmunoassay was suitable for direct determination of [D-Trp6]LH-RH in serum, permitting the study of blood levels of the analog after single injections into normal men and after once-a-month administration of microcapsules to rats. In men, 90 min after subcutaneous injection of 250 micrograms of the peptide, serum [D-Trp6]LH-RH rose to 6-12 ng/ml. Luteinizing hormone was increased 90 min and 24 hr after the administration of the analog. Several batches of microcapsules were tested in rats and the rate of release of [D-Trp6]LH-RH was followed. The improved batch of microcapsules of [D-Trp6]LH-RH increased serum concentrations of the analog for 30 days or longer after intramuscular injection. This was accompanied by suppression of testosterone levels for more than 30 days. This radioimmunoassay should be of value for monitoring [D-Trp6]LH-RH during long-term therapy.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D017329 Triptorelin Pamoate A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6. D-Trp-6-LH-RH,LHRH, Trp(6)-,Triptorelin,6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig),AY-25650,CL-118532,Decapeptyl,Decapeptyl Depot,Decapeptyl LP,Decapeptyl Trimestral,GnRH, Trp(6)-,LHRH, Tryptophyl(6)-,Trelstar,Triptorelin Embonate,Wy-42462,AY 25650,AY25650,CL 118532,CL118532,Embonate, Triptorelin,Pamoate, Triptorelin,Trimestral, Decapeptyl,Wy 42462,Wy42462
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations.
August 1988, Proceedings of the National Academy of Sciences of the United States of America,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration.
April 1986, Regulatory peptides,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
April 1985, Proceedings of the National Academy of Sciences of the United States of America,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins.
January 1989, Fertility and sterility,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Radioimmunoassay of nafarelin ([ 6-(3-(2-naphthyl)-D-alanine)]-luteinizing hormone-releasing hormone) in plasma or serum.
August 1984, Analytical biochemistry,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
D-Tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia.
April 1982, International journal of andrology,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man.
September 1981, The Journal of clinical investigation,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Follicle cyst formation following long-acting gonadotropin-releasing hormone analog administration.
December 1989, Fertility and sterility,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons.
May 1985, Proceedings of the National Academy of Sciences of the United States of America,
M Mason-Garcia, and S Vigh, and A M Comaru-Schally, and T W Redding, and A Somogyvari-Vigh, and J Horvath, and A V Schally
Flexible menotropins initiation after long-acting gonadotropin-releasing hormone analog.
November 1989, Fertility and sterility,
Copied contents to your clipboard!